Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT by Defilipp, et al.
Metabolic syndrome and cardiovascular disease following 
hematopoietic cell transplantation: screening and preventive 
practice recommendations from CIBMTR and EBMT
Z DeFilipp1, RF Duarte2, JA Snowden3, NS Majhail4, DM Greenfield5, JL Miranda6, M Arat7, 
KS Baker8, LJ Burns9, CN Duncan10, M Gilleece11, GA Hale12, M Hamadani13, BK 
Hamilton4, WJ Hogan14, JW Hsu15, Y Inamoto16, RT Kamble17, MT LupoStanghellini18, AK 
Malone19, P McCarthy20, M Mohty21,22,23, M Norkin15, P Paplham20, M Ramanathan24, JM 
Richart25, N Salooja26, HC Schouten27, H Schoemans28, A Seber29,30, A Steinberg19, BM 
Wirk31, WA Wood32, M Battiwalla33, MED Flowers8, BN Savani34, and BE Shawon13 on 
behalf of the CIBMTR Late Effects and Quality of Life Working Committee and the EBMT 
Complications and Quality of Life Working Party
1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 
Atlanta, GA, USA 2Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain 
3Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and 
Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK 4Department of 
Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA 5Specialized Cancer Services, 
Sheffield Teaching Hospital NHS Foundation Trust, Shefflied, UK 6Department of Medicine, Reina 
Sofia University Hospital, Maimonides Institute for Biomedical Research at Cordoba (IMIBIC), 
University of Cordoba, CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de 
Salud Carlos III, Cordoba, Spain 7Florence Nightingale Sisli Hospital, Hematopoietic Stem Cell 
Transplantation Unit, Istanbul, Turkey 8Clinical Research Division, Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA 9National Marrow Donor Program, University of Minnesota, 
Minneapolis, MN, USA 10Pediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Boston, 
MA, USA 11Leeds Teaching Hospitals NHS Trust, Leeds, UK 12All Children's Hospital, John 
Hopkins Medicine, St. Petersburg, FL, USA 13Department of Medicine, Center for International 
Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, 
WI, USA 14Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, 
USA 15Division of Hematology & Oncology, Department of Medicine, University of Florida, 
Gainesville, FL, USA 16Division of Hematopoietic Stem Cell Transplantation, National Cancer 
Center Hospital, Tokyo, Japan 17Division of Hematology and Oncology, Center for Cell and Gene 
Therapy, Baylor College of Medicine, Houston, TX, USA 18Hematology and Bone Marrow 
Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy 19Division of Hematology/
Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, 
USA 20Department of Medicine, Roswell Park Cancer Institute, BMT Program, Buffalo, NY, USA 
Corresponding Author: Bronwen Shaw, MD PhD, Department of Medicine, Center for International Blood and Marrow Transplant 
Research, Medical College of Wisconsin 9200 W Wisconsin Ave, Milwaukee, WI 53226, Phone: 414-805-0700, Fax: 414-805-0714, 
beshaw@mcw.edu. 
Conflict of Interest: The authors declare no conflict of interest.
HHS Public Access
Author manuscript
Bone Marrow Transplant. Author manuscript; available in PMC 2018 February 01.
Published in final edited form as:
Bone Marrow Transplant. 2017 February ; 52(2): 173–182. doi:10.1038/bmt.2016.203.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
21University Pierre & Marie Curie, Paris, France 22Hopital Saint-Antoine, AP-HP, Paris, France 
23INSERM UMRs 938, Paris, France 24Department Hematology, Oncology and Bone Marrow 
Transplant, UMass Memorial Medical Center, Worcester, MA, USA 25Division of Hematology and 
Medical Oncology, Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA 
26Hammersmith Hospital, London, UK 27Maastricht University Medical Center, Maastricht, The 
Netherlands 28Department of Hematology, University Hospital Leuven and KU Leuven, Leuven, 
Belgium 29Hospital Samaritano, Sao Paulo, Brazil 30Associação da Medula Ossea - AMEO, Sao 
Paulo, Brazil 31Department of Internal Medicine, Stony Brook University Medical Center, Stony 
Brook, NY, USA 32Division of Hematology/Oncology, Department of Medicine, University of North 
Carolina, Chapel Hill, NC, USA 33Hematology Branch, National Institutes of Health, Bethesda, 
MD, USA 34Division of Hematology/Oncology, Department of Medicine, Vanderbilt University 
Medical Center, Nashville, TN, USA
Abstract
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk 
of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of 
hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and 
cardiovascular disease, with the estimated prevalence of MetS being 31–49% among HCT 
recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an 
understanding of the incidence and risk factors for MetS in HCT recipients can provide the 
foundation to evaluate screening guidelines and develop interventions that may mitigate 
cardiovascular-related mortality. A working group was established through the Center for 
International Blood and Marrow Transplant Research and the European Group for Blood and 
Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate 
to HCT recipients. Here we deliver consensus recommendations to help clinicians provide 
screening and preventive care for MetS and cardiovascular disease among HCT recipients. All 
HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended 
screening based on their predisposition and ongoing risk factors.
Introduction
Advances in hematopoietic cell transplantation (HCT) and supportive care have led to 
substantial improvements in transplant outcomes and an increased number of long-term 
HCT survivors.1 Transplant survivors are at considerable risk for developing significant late 
effects and experience mortality rates higher than the general population.2,3 One challenge 
faced in the post-HCT setting is the development of metabolic syndrome (MetS), with 
reported prevalence rates of 31–49%.4–8 HCT recipients are predisposed to develop MetS 
through several mechanisms, including conditioning regimen-mediated damage to the 
neurohormonal system and vascular endothelium, as well as the immunological and 
inflammatory effects of allografting (including subsequent GvHD and its therapy).4 
Individuals in the general population with MetS are twice as likely to develop cardiovascular 
disease than those without MetS.9 A better understanding of MetS following HCT may 
prove to be significant, as HCT survivors are known to be at increased risk for 
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cardiovascular morbidity and mortality. In the Bone Marrow Transplant Survivor Study 
(BMTSS), the risk of premature cardiovascular-related death following HCT was found to 
be increased 2.3-fold compared with the general population.2,3 Similarly, others have 
reported the risk of cardiovascular hospitalizations and mortality to be increased by 3.6-fold 
in HCT recipients compared with the general population.10
Intensive chemotherapy and radiation have been associated with MetS and contribute to the 
development of this syndrome post HCT, especially in heavily pre-treated populations.11,12 
MetS has not yet been proven to impact cardiovascular risk after HCT. However, an 
understanding of the incidence and risk factors for MetS and cardiovascular disease 
following HCT provides the foundation to evaluate screening guidelines and develop 
interventions that may mitigate cardiovascular-related mortality. Therefore, a collaboration 
was established between the Center for International Blood and Marrow Transplant 
Research (CIBMTR) Late Effects and Quality of Life Working Committee and the European 
Group for Blood and Marrow Transplantation (EBMT) Complications and Quality of Life 
Working Party with the goal to review literature, including previously published guidelines 
for screening and preventive practices for HCT survivors.13–15 We subsequently provide 
specific screening and preventive practice recommendations for MetS and cardiovascular 
disease appropriate to HCT recipients based on published evidence and expert opinion.
Metabolic Syndrome
MetS is a cluster of interrelated factors that increases the risk of cardiovascular disease, 
diabetes mellitus (DM) and all cause mortality.16–18 The International Diabetes Foundation 
(IDF) estimates that 25% of the world's adult population has MetS.19 The four core clinical 
measures are increased body weight/visceral adiposity, elevated lipids, raised blood pressure 
(BP) and hyperglycemia/insulin resistance (IR).20 The individual diagnostic criteria of MetS 
have varied over time according to the different definitions applied. The diagnostic criteria 
of the National Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATPIII),9,21 the IDF, and the American Heart Association (AHA)17 and the World Health 
Organization22 are shown in Table 1. A comparison of various definitions in terms of their 
predictive value established that the prevalence of MetS was significantly greater when using 
the criteria of the AHA and IDF compared with the NCEP ATPIII definition.23 However, the 
risks of cardiovascular events and death were markedly greater for participants who satisfied 
any of the criteria for diagnosis of MetS compared with healthy individuals. This supports 
other reports that found agreement between MetS components and cardiovascular risk 
factors in the general population.24,25
Abdominal Obesity
Obesity, defined as a body mass index (BMI) ≥ 30 kg/m2, affects 35% of adults in the 
United States of America26 and 10–30% of adults in Europe.27 Obese persons have a higher 
risk of developing serious medical conditions, including hypertension (HTN), dyslipidemia, 
type 2 DM, coronary heart disease (CHD) and ischemic stroke, and have a higher mortality 
than the non-obese population.28 However, BMI is an insufficient measure of abdominal 
obesity. Waist circumference, which emphasizes visceral adipose deposits, is preferentially 
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used in the evaluation of abdominal obesity when defining MetS (Table 1) as this 
distribution of fat accumulation independently confers cardiometabolic risk.29,30 Yet, as 
studies reporting waist circumference at the time of and following HCT are limited, BMI 
may act as a possible surrogate.
BMI ≥ 35 kg/m2 (severely obese) ‘has been part of’ the HCT- specific comorbidity index 
since 2005, as this was determined to be a risk factor for increased non-relapse 
mortality.31–34 While pre-transplant obesity can influence body composition following HCT, 
changes in waist circumference can be seen independent of pre- existing obesity. Despite 
what may be a normal BMI, HCT survivors are at an increased risk to develop sarcopenic 
obesity (increase in percent fat mass, decrease in lean body mass), which can significantly 
contribute to IR.35,36 A longitudinal study using dual-X-ray absorptiometry to calculate 
body fat mass index in 82 patients found the prevalence of a high body fat mass index was 
greater at 2–3 years following allo-HCT than in healthy controls.37 Corticosteroids, which 
remain the first-line treatment of GvHD, contribute to sarcopenic obesity by promoting 
muscle atrophy and may contribute to obesity in the early post-HCT period.5,38 Robust data 
on the changes in abdominal obesity following autologous HCT (auto-HCT) are lacking. 
One study evaluated metabolic and body composition changes in 32 patients with multiple 
myeloma who had received three lines of intensive treatment including at least one HCT. At 
a median duration of 6 years from diagnosis, dual-X-ray absorptiometry identified 
sarcopenic obesity in 65% of patients.39 Importantly, the development of sarcopenic obesity 
following HCT has yet to be independently associated with increased cardiovascular 
mortality. In the pediatric population, a cross-sectional study evaluating 54 allo-HCT 
survivors and 894 healthy participants found a deficiency in lean mass (as identified by dual-
X-ray absorptiometry) as compared with fat mass in HCT survivors.40 A prospective, 
descriptive cross-sectional study evaluating children and adolescents for the development of 
MetS post HCT found that 73% of individuals with this diagnosis had a characteristic of 
abdominal obesity (abdominal circumference 475th percentile by age and gender).5
Screening and preventive recommendations
The United States Preventive Services Task Force (USPSTF) and the National Heart, Lung, 
Blood Institute (NHLBI) recommend screening for obesity in all adults and children 42 
years of age, though no recommendation is made regarding appropriate intervals for 
screening. Current guidelines for HCT recipients do not provide specific screening 
recommendations for abdominal obesity, though education and counseling regarding regular 
exercise, healthy weight and dietary counseling are encouraged.14,15 Given the increase in 
abdominal obesity that can occur after HCT, clinicians should consider monitoring body 
composition at each visit, with regular measurement of height, weight and waist 
circumference (at least yearly). Based on what is known in other populations, we 
recommend that patients with a BMI ≥ 30 kg/m2, waist circumference >102 cm (>40 inches) 
in men or >88 cm (>35 inches) in women or significant increases in either of these 
measurements should be considered for intensive, multicomponent behavioral interventions. 
Dual-X-ray absorptiometry may be used to assist evaluation and monitoring of changes in 
body composition in survivors of HCT.
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Dyslipidemia
Dyslipidemia, defined as elevated levels of total cholesterol, low-density lipoprotein 
cholesterol or triglycerides, or low levels of high-density lipoprotein (HDL) cholesterol, is 
an important risk factor for CHD and ischemic stroke.41,42 The prevalence of dyslipidemia is 
high in the general population: in 2000, ∼ 25% of adults in the United States of America had 
total cholesterol greater than ≥ 240 mg/dL (≥6.2 mmol/L) or were taking lipid-lowering 
medication.43 A high prevalence of dyslipidemia has also been reported in European 
countries.44,45 Of the various dyslipidemias, low HDL (<40– 50 mg/dL, <1.0–1.3 mmol/L) 
and hypertriglyceridemia (>150 mg/dL, >1.7 mmol/L) have been incorporated into the 
diagnostic criteria of MetS (Table 1).
Survivors of allo-HCT are at an increased risk of post-transplant dyslipidemia. In a 
retrospective cohort study comparing incidence and risk factors for cardiovascular events, 
allo-HCT recipients had significantly higher risk of new onset dyslipidemia (relative risk 
(RR): 2.31; 95% confidence interval (CI), 1.15–4.65) compared with auto-HCT recipients.46 
Single-institution studies have estimated the incidence of hypercholesterolemia and/or 
hypertriglyceridemia following allo-HCT to be 43– 73%.47,48 The onset of dyslipidemia 
post HCT can be rapid, with the median interval to the development of hypertriglyceridemia 
and hypercholesterolemia being 8 and 11 months following allo-HCT, respectively, in one 
single-center experience.47 Factors predicting development of post-HCT dyslipidemia 
include family history of hyperlipidemia, obesity, high-dose TBI, grade II–IV acute GvHD, 
chronic GvHD and chronic liver disease.5,8,47–49 In addition, immunosuppressant 
medications (for example, sirolimus, calcineurin inhibitors and corticosteroids) not only 
increase lipid levels but also lead to significant drug–drug interactions with 3-hydroxy-3-
methylgutaryl–CoA reductase inhibitors (statins) via the cytochrome p450 pathway.50,51 
Data regarding the incidence of dyslipidemia following auto-HCT are limited. In a single-
center analysis evaluating late post-HCT cardiovascular complications in 1379 patients, 
which included both auto- and allo-HCT recipients, 1 year post-HCT dyslipidemia requiring 
treatment was associated with an increased risk for stroke (hazard ratio = 7.4; 95% CI, 1.2–
47).52 In the pediatric population, the risk of hypercholesterolemia is high in childhood 
cancer survivors who underwent auto-HCT (hazard ratio = 3.2; CI, 1.7–5.9).53
Screening and preventive recommendations
The USPSTF strongly recommends screening for lipid disorders every 5 years in men ≥ 35 
years, women ≥ 45 years and persons ≥ 20 years at increased risk for CHD, whereas the 
NHLBI recommends screening in children between the ages of 9–11 years or earlier in those 
with family history. Current guidelines for HCT recipients recommend similar screening 
practices for dyslipidemia among the general population.14,15 We recommend standard risk 
patients (including auto-HCT recipients without personal risk factors) should follow these 
guidelines. However, early onset of dyslipidemia following allo-HCT is not uncommon, 
especially in high-risk patients. Thus, we propose early assessment of exposures and risk 
factors in all HCT patients. For recipients of alloHCT, we suggest an initial lipid profile 3 
months after HCT. For high-risk patients with ongoing risk factors (including those on 
sirolimus, calcineurin inhibitors and corticosteroids), we suggest repeat evaluation every 3–6 
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months. In recipients without ongoing risk factors, we suggest repeat evaluation according to 
recommendations for the general population. Non-pharmacologic management of 
dyslipidemia primarily involves lifestyle modifications such as diet (low saturated fat and 
low cholesterol), exercise (or other regular physical activities), weight reduction, smoking 
cessation and limiting alcohol intake. Although not validated among HCT survivors, we 
recommend use of the Framingham risk score (http://cvdrisk.nhlbi.nih.gov) to assess 
cardiovascular risk and guide therapy decisions.41 The safety of lipid-lowering agents must 
be considered in the pediatric population, as the AHA recommends considering drug therapy 
for high-risk lipid abnormalities in boys ≥ 10 years of age and after onset of menses in girls, 
preferably after a 6–12 month trial of saturated fat- and cholesterol-restricted dietary 
management.54
Hypertension
HTN, defined as a systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg, is a worldwide 
epidemic affecting ∼ 25% of adults.55 Of note, the BP criteria used in most definitions of 
MetS is systolic BP ≥ 135 mm Hg or diastolic BP ≥ 85 mm Hg (or drug treatment for HTN) 
(Table 1), which is classified as pre-HTN according to the report from the Eighth Joint 
National Committee.56
An analysis of the BMTSS showed that after adjustment for age, sex, race and BMI, allo-
HCT recipients were 2.06 times (95% CI, 1.39–3.04) more likely to report HTN as 
compared with sibling donors or auto-HCT recipients, who had a similar risk (odds ratio, 
0.96; 95% CI, 0.65–1.44).57 Similarly, a retrospective, single- institution evaluation of 265 
long-term transplant survivors reported that allo-HCT recipients have an increased risk of 
HTN (RR: 2.50; 95% CI, 1.19–5.27) compared with auto-HCT patients.46 A direct cause 
and effect relationship of conditioning regimen, acute or chronic GvHD and HTN was not 
established.57 Two large retrospective studies did not show a significant difference in the 
incidence of HTN in allo-HCT recipients with or without GvHD.57,58 It appears that HTN is 
related to use of certain GvHD therapies (for example, calcineurin inhibitors, steroids) rather 
than GvHD- induced pro-inflammatory cytokine response and endothelial damage. 
Although pediatric patients are less likely than adults to have pre-transplant HTN as well as 
any risk factors for HTN, an analysis of 1 year survivors of allo-HCT found a similar 
incidence of post-HCT HTN in adult (68%) and pediatric (73%) HCT survivors.59 In 
multivariate analyses, exposure to cyclosporine increased the risk of HTN post HCT (RR: 
1.6; 95% CI, 1.1–2.5), but only within the first 2 years, suggesting this may revert once 
medications are stopped.
Screening and preventive recommendations
The USPSTF recommends BP assessment every 3–5 years in adults aged 18–39 years with 
normal BP (<130/85 mm Hg) who do not have other risk factors and annually in adults aged 
≥ 40 years and for those who are at increased risk of high BP. In children, the NHLBI 
recommends BP assessment yearly after the age of 3 years, interpreted for age, sex and 
height. Current guidelines for HCT recipients recommend at least annual BP assessment in 
children and BP assessment every other year in adults.14,15 We recommend BP assessment 
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for HCT recipients at every clinic visit (at least yearly). The Joint National Committee 8 
report recommends initiating pharmacologic treatment for BP of ≥ 150/≥ 90 mm Hg in 
persons ≥ 60 years of age (to a BP goal of <150/<90 mm Hg) and for BP of ≥ 140/≥ 90 in 
persons 30–59 years of age (to a BP goal of <140/<90).56 In the absence of HCT-specific 
evidence, these goals can be used to guide management of HCT recipients, but other factors, 
such as end organ compromise (cardiac or renal failure) and therapy with calcineurin 
inhibitors, also need to be taken into account.
Insulin Resistance/Diabetes Mellitus
DM, which affects almost 10% of the adult population worldwide, is characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action or both. The chronic 
hyperglycemia of DM is associated with long-term damage, dysfunction and failure of 
various organs, especially the eyes, kidneys, nerves, heart and blood vessels. The American 
Diabetes Association defines DM as a fasting plasma glucose ≥ 126 mg/dL (≥7 mmol/L), a 
hemoglobin A1C (HbA1C) ≥ 6.5%, a 2-h plasma glucose ≥ 200 mg/dL (≥11.1 mmol/L) 
during an oral glucose tolerance test, or a random glucose ≥ 200 mg/dl (≥11.1 mmol/L) in a 
patient with classic symptoms or hyperglycemia or hyperglycemic crisis.60 Impaired fasting 
glucose (fasting glucose 100–126 mg/dL (5.6– 7 mmol/L)) or DM are used in most 
definitions of MetS (Table 1). The treatment of DM may reduce the progression of 
microvascular and cardiovascular disease.61–64 Although randomized trials have failed to 
demonstrate an unequivocal benefit, the identification of patients by screening allows for 
earlier intervention with potential reduction in complications.65,66
While hyperglycemia and impaired glucose tolerance are well-recognized complications of 
cancer and GvHD treatment (corticosteroids), data regarding the long-term risk of DM in 
HCT survivors are limited.67 In the BMTSS, both allo-HCT (odds ratio, 3.65; 95% CI, 1.82–
7.32) and auto-HCT (odds ratio, 2.03; 95% CI, 0.98–4.21) recipients were more likely to 
report DM than sibling donors.57 The incidence of post-HCT DM was 30% among 1 year 
allo-HCT recipients in both adult and pediatric populations.59 In this study, exposure to 
high-dose corticosteroids (cumulative prednisone dose of <0.25 mg/kg/day) increased the 
likelihood of developing DM (RR: 3.6; 95% CI, 1.7–7.5) and for having persistent DM at 2 
years post HCT (RR: 4.1; 95% CI, 1.0–18.2). While data regarding the incidence of IR in 
survivors of adult HCT are lacking, the incidence of IR for pediatric HCT survivors has been 
estimated to be 10– 52% in single-center studies.68–71 These reports suggest an increased 
risk for IR/DM in survivors of both allo- and auto-HCT compared with patients treated with 
chemotherapy alone or untreated siblings, even when off immunosuppressive treatments. 
Preliminary data from a cross-sectional study including 151 HCT survivors (76.8% allo-
HCT) and 92 sibling controls found HCT survivors who had received TBI conditioning to be 
significantly more likely to have IR than their sibling controls, but there was no increased 
risk of IR for those patients who had a history of acute or chronic GvHD (KS Baker, 
personal communication). Multiple studies found high-dose TBI as a risk factor for IR and 
impaired glucose tolerance, in addition to older age and lipodystropic body type.70–73 
Although data have not demonstrated an increased risk of diabetes to be directly associated 
with history of GvHD, further study is warranted.
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Screening and preventive recommendations
The most common tests to screen for diabetes are fasting plasma glucose, 2 h plasma 
glucose during an oral glucose tolerance test and HbA1C. The USPSTF recommends 
screening for abnormal blood glucose (HbA1C, fasting plasma glucose or oral glucose 
tolerance test) every 3 years in adults aged 40–70 years who are overweight or obese. The 
NHLBI recommends screening with a fasting glucose every 2 years after the age of 10 years 
in overweight children with other risk factors. Current guidelines for HCT recipients 
recommend screening for type 2 DM every 3 years in adults aged ≥ 45 years or in those with 
sustained higher BP (<135/80 mm Hg) and fasting glucose at least every 5 years in pediatric 
survivors,14,15 which should be appropriate for standard risk patients. For high-risk patients 
with ongoing risk factors (including those on systemic corticosteroids), we recommend 
screening for abnormal blood glucose (HbA1C or fasting plasma glucose) 3 months after 
HCT with repeat evaluation every 3–6 months. For patients with impaired fasting glucose, 
we encourage weight reduction and increased physical activity, whereas patients with type 2 
DM should implement lifestyle therapy and pharmacotherapy, if necessary, to achieve near-
normal HbA1C (<7%).
Coronary Heart Disease
More people die from cardiovascular disease each year than from any other cause. 
Cardiovascular disease is caused by disorders of blood vessels and is closely related to 
atherosclerosis, where endothelial lesions occur up to decades before clinical 
manifestations.74,75 Risk factors for arteriosclerosis in the general population are well 
established and include smoking, arterial HTN, obesity, DM, dyslipidemia, familial history 
of CHD, physical inactivity, male gender and elevated C-reactive protein.76
Several studies have attempted to assess the incidence of cardiovascular disease after HCT, 
with or without a comparison with a control population. A retrospective multicenter EBMT 
analysis showed that 3.6% of long-term allo-HCT survivors transplanted between 1990 and 
1995 had a cardiovascular event in at least one arterial territory observed.77 The cumulative 
incidence of a first cardiovascular event 15 years after HCT was 6% (95% CI, 3–10%). One 
study reported a cumulative incidence of 7.5% for the first cardiovascular event at 15 years 
post allo-HCT, as compared with 2.3% post auto-HCT.46 In multivariate analysis, allo-HCT, 
in addition to at least 2 of 4 cardiovascular risk factors (HTN, dyslipidemia, DM and 
obesity) was associated with a higher incidence of cardiovascular events (RR: 12.4; P = 
0.02). In a retrospective cohort study, ≥ 2 year HCT survivors experienced an increased 
incidence of cardiovascular death (adjusted incidence rate difference, 3.6 per 1000 person-
years (95% CI, 1.7–5.5) when compared with the general population.10 In this study, an 
increased cumulative incidence was also found for ischemic heart disease, cardiomyopathy 
or heart failure, stroke, vascular diseases, and rhythm disorders and an increased incidence 
of related conditions that predispose toward more serious cardiovascular disease (HTN, renal 
disease, dyslipidemia and DM). In another study, HCT recipients had significantly higher 
rates of cardiomyopathy (4.0% vs 2.6%), stroke (4.8% vs 3.3%), dyslipidemia (33.9% vs 
22.3%) and DM (14.3% vs 11.7%) (P <0.05 for all comparisons) than the general 
population, though lower rates of ischemic heart disease (6.1% vs 8.9%; P <0.01).49 In the 
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BMTSS, survivors of both allo- and auto-HCT were not more likely to report arterial 
disease, myocardial infarction or stroke than sibling donors.57 One series, which included 
42.7% allo-HCT recipients, reported an incremental increase in 10-year incidence of 
cardiovascular disease by number of cardiovascular risk factors (4.7% (no factor), 7.0% (one 
risk factor), 11.2% (≥2 risk factors), P <0.01); the risk was especially high (15.0%) in 
patients with multiple risk factors and pre-HCT exposure to anthracyclines or chest 
radiation.78 In the adult population, it is important to acknowledge that an increasing number 
of older patients are undergoing allo-HCT with reduced intensity conditioning and that 
future studies are needed to assess the incidence of cardiovascular complications in this 
population.
In children with acute lymphoblastic leukemia, high-dose TBI and cranial irradiation 
correlated with multiple adverse cardiovascular factors including central adiposity, HTN, IR 
and dyslipidemia.79,80 Some studies have analyzed the correlation with GvHD and either 
found a correlation81 or not46,57 and if so, more likely with acute than chronic GvHD.77,78
Screening and preventive recommendations
In the general population, a person's 10-year risk for CHD is determined based on age, 
gender and conventional CHD risk factors such as smoking, HTN and dyslipidemia 
(Framingham risk score, http://cvdrisk.nhlbi.nih.gov).82 Overall, the benefits of screening 
with resting or exercise electrocardiography or for non-traditional risk factors, including 
coronary artery calcification on electron beam computerized tomography, have not been 
clearly demonstrated to outweigh harms. The USPSTF recommends against screening with 
electrocardiography in asymptomatic adults with low risk for CHD and concludes that there 
is insufficient evidence to assess the balance of benefits and harms of screening with resting 
or exercise electrocardiography in asymptomatic adults at intermediate or high risk for CHD 
events. Similarly, the USPSTF finds insufficient evidence to assess the balance of benefits 
and harms of using non-traditional risk factors to screen asymptomatic men and women with 
no history of CHD to prevent CHD events. Current guidelines for HCT recipients do not 
provide specific screening recommendations for CHD.14 Decisions about screening in adults 
at increased risk should be made on a case-by-case basis and after careful discussion with 
the patient about the risks and benefits of screening. Although little data are available about 
specific interventions in the HCT populations, we recommend a similar approach.
Ischemic Stroke
Stroke is the fourth leading cause of death in the United States of America, whereas globally 
it is the second most common cause of mortality and the third most common cause of 
disability.83,84 Globally, stroke incidence from ischemia is 68 and 32% from hemorrhagic 
stroke (intracerebral and subarachnoid combined).85 Pediatric stroke is one of the top ten 
causes of death in children, occurring at 11 per 100 000 children per year, with acute 
ischemic stroke accounting for half of all cases.86–88
The cumulative incidence of stroke after adult HCT has been reported in single-center series 
to be 1–5% at a median of 4–10 years following HCT.10,46,49,79,89 In one study of 3833 
HCT survivors of ≥ 1 year (71.3% allo-HCT), the prevalence of stroke at a median of 10.8 
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years since HCT was slightly higher than in a matched general population sample (4.8% vs 
3.3%).49 Reported risk factors for stroke include hyperlipidemia, suboptimal physical 
activity, HTN treatment before HCT, BMI ≥ 30 kg/m2 at HCT and recurrence of the original 
disease.10,49,52 The risk of stroke did not differ statistically between auto- or allo-HCT, 
gender, age at HCT, TBI dose, smoking history, donor type, stem cell source, fruit or 
vegetable intake and prior cranial radiation.10,49,52,57 A history of chronic GvHD was 
associated with an increased risk of stroke among ≥ 5-year HCT survivors (odds ratio, 2.0; 
95% CI, 1.1–3.6) in one study,49 whereas it was not statistically associated with risk of 
stroke in the other studies. Although ischemic stroke is an indication for HCT in sickle cell 
disease, reports indicate that there is no increased risk post HCT in this population. In one 
report of pediatric sickle cell disease patients, two had transient ischemic attacks after allo-
HCT but not stroke.90 Similarly, another study of pediatric sickle cell disease matched 
related allo-HCT patients did not report stroke in those with successful engraftment.91 Adult 
sickle cell disease may have a higher risk of stroke and allo-HCT studies in the adult 
population are ongoing.
Although the reported incidence of stroke in HCT survivors is low, it may be under 
recognized due to under reporting. Central nervous system complications—such as stroke, 
posterior reversible encephalopathy syndrome and seizures—also occur frequently in the 
early post-HCT follow up with significant impact on patient survival.92 Beside the well-
known posterior reversible encephalopathy syndrome, calcineurin inhibitors may cause a 
reversible cerebral vasoconstriction syndrome that can progress to cerebral infarction.93 
Furthermore neurovascular complications— including stroke and transient ischemic attacks
—occur commonly upon initial presentation of thrombotic microangiopathies presentation 
and cryptogenic stroke may develop before the onset of alarming hematologic 
abnormalities.94,95
Screening and preventive recommendations
The risk of a first stroke can be assessed by a global risk assessment tool such as the AHA/
American College of Cardiology Cardiovascular Risk Calculation online tool for adults 
(http://my. americanheart.org/cvriskcalculator), which has also been endorsed by the 
American Academy of Neurology.96 The USPSTF recommends against screening for 
asymptomatic carotid artery stenosis in the general adult population. Preventive practice 
includes performing moderate to vigorous aerobic physical activity for at least 40 min 3–4 
times a week, statin therapy according to 10 year calculated cardiovascular risk, 
implementation of a Mediterranean diet, HTN therapy and weight loss in overweight and 
obese patients. Current guidelines for HCT recipients do not provide specific screening 
recommendations for stroke.14 In the absence of HCT-specific evidence, these goals 
represent appropriate guidelines for HCT recipients.
Recommendations for Screening and Preventive Practices
Although evidence demonstrating the benefits of screening and preventive practices in HCT 
survivors is lacking, this review of MetS and cardiovascular disease emphasizes the high 
incidence of cardiovascular risk factors and the related morbidity and mortality experienced 
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by HCT recipients. Based on these data, we present published guidelines for the general 
population and HCT survivors (Tables 2 and 3), as well as our consensus recommendations 
on the screening and preventive practices (Table 4) for MetS and cardiovascular disease. We 
also present risk factors to consider when screening for components of MetS in transplant 
recipients (Table 5). HCT survivors with no identifiable risk factors should be counseled to 
have a healthy lifestyle and to follow the well-established screening recommendations for 
the healthy population. However, high-risk patients with ongoing risk factors should be more 
closely monitored.
Although not addressed formally in this manuscript, endocrine abnormalities, such as male 
hypogonadism, premature menopause and hypothyroidism, can occur following HCT and 
may contribute to MetS cardiovascular risk. Health care providers should be aware of these 
risks and evaluate for these conditions in HCT survivors, especially in the presence of MetS 
or those with risk factors.
A number of online tools are available to help providers assess risk in patients. In addition to 
the Framingham risk score (http://cvdrisk.nhlbi.nih.gov), the AHA released a mobile 
application in 2013 (http://tools.acc.org/ASCVD-Risk-Estimator) to estimate 10 year and 
lifetime risks for atherosclerotic cardiovascular disease in healthy subjects considering age, 
ethnicity, gender, systolic BP, history of smoking and DM, total and HDL cholesterol. 
However, these calculators were designed for the general population and have limitation by 
age, ethnicity and/or comorbid conditions. Furthermore, it is important to acknowledge that 
these tools have not been validated in HCT survivors and thus potentially underestimate risk 
in this population.
Conclusion
We provide consensus recommendations for screening and preventive measures for MetS 
and cardiovascular disease in recipients of HCT. Such effort by the CIBMTR and EBMT 
Late Effects Working Groups is intended to raise awareness of the cardiovascular risk in 
HCT survivors and lead to practices that will decrease related mortality. This document does 
not discuss strategies to achieve these practices (for example, survivorship clinics, 
rehabilitation or exercise programs) given the differences in health-care environments 
between different countries, but efforts to facilitate such strategies to be developed at the 
local or national level are needed.
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Table 1
Definitions of metabolic syndrome according to the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATPIII), the International Diabetes 
Federation (IDF), the American Heart Association (AHA), and the World Health 
Organization (WHO)
NCEP ATPIII [21] IDF [26] AHA [9] WHO [23]
Definition ≥3 risk factors Increased waist 
circumference plus ≥2 
risk factors
≥3 risk factors DM/IFG or IGT or IR 
plus ≥2 risk factors
Risk Factor
Abdominal Obesity Waist circumference: >102 cm 
(>40 in) in men; >88 cm (>35 
in) in women
Waist circumference: 
dependent on ethnicity
Waist circumference: 
>102 cm (>40 in) in men; 
>88 cm (>35 in) in 
women
Waist circumference: 
dependent on ethnicity
Triglycerides ≥150 mg/dL (≥1.7 mmol/L) or 
drug treatment for elevated 
levels
≥150 mg/dL (≥1.7 
mmol/L) or drug 
treatment for elevated 
levels
≥150 mg/dL (≥1.7 
mmol/L) or drug 
treatment for elevated 
levels
≥150 mg/dL (≥1.7 
mmol/L)
HDL cholesterol
 Men <40 mg/dL (<1.0 mmol/L) or 
drug treatment for reduced 
levels
<40 mg/dL(<1.0 mmol/L) 
or drug treatment for 
reduced levels
<40 mg/dL(<1.0 mmol/L) 
or drug treatment for 
reduced levels
<35 mg/dL (0.9 
mmol/L)
 Women <50 mg/dL (<1.3 mmol/L) or 
drug treatment for reduced 
levels
<50 mg/dL (<1.3 
mmol/L) or drug 
treatment for reduced 
levels
<50 mg/dL(<1.3 mmol/L) 
or drug treatment for 
reduced levels
<39 mg/dL (1.0 
mmol/L)
Blood Pressure ≥130/≥85 mmHg or drug 
treatment for HTN
≥130/≥85 mmHg or drug 
treatment for HTN
≥130/≥85 mmHg or drug 
treatment for HTN
≥140/≥90 mmHg
Fasting Glucose ≥110 mg/dL (≥6.11 mmol/L) or 
drug treatment for DM
≥100 mg/dL (≥5.6 
mmol/L) or drug 
treatment for DM
≥100 mg/dL (≥5.6 
mmol/L) or drug 
treatment for DM
IGT, IFG, or type 2 DM
Microalbuminuria >30 mg albumin/g 
creatinine
DM: diabetes mellitus
HDL: high-density lipoprotein cholesterol
HTN: hypertension
IGT: impaired glucose tolerance (2-hour postprandial glucose 140-199 mg/dL (7.8-11.1 mmol/L))
IFG: impaired fasting glucose (fasting glucose 100-126 mg/dL (5.6-7 mmol/L))
IR: insulin resistance
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Table 3
Preventive practice recommendations for metabolic syndrome and cardiovascular risk 
factors for adult and pediatric patients amongst the general population and HCT 
survivors
General adult 
population
(Grundy. 
Circulation. 2005)
Adult long-term 
HCT survivors
(Majhail. BBMT. 
2012)
General pediatric population
(http://www.nhlbi.nih.gov)
Our recommendations
(CIBMTR/EBMT MetS 
collaboration)
Weight control Recommend 
behavioral changes to 
reduce caloric intake 
and increase physical 
activity
Recommend 
education and 
counseling on 
“heart” healthy 
lifestyle (regular 
exercise, healthy 
weight, no smoking, 
dietary counseling)
Combined weight loss programs 
that include behavior change 
counseling, negative energy 
balance through diet, and 
increased physical activity
Provide advice regarding 
intensive, multicomponent 
behavioral interventions 
focused on achieving and 
maintaining healthy weight 
by reducing caloric intake 
and increasing physical 
activity
Dyslipidemia control Non-pharmacologic 
treatments include 
weight reduction, 
increased physical 
activity, and 
antiatherogenic diet
Lifestyle 
modifications and 
lipid lowering 
therapies to achieve 
risk-adapted target for 
LDL is primary goal, 
even in MetS.
Once LDL is at target, 
further lipid lowering 
therapy can be added 
to achieve targets for 
HDL and TG.
If TG>500 mg/dL 
(5.65 mmol/L), 
initiate fibrate or 
nicotinic acid
Recommend 
education and 
counseling on 
“heart” healthy 
lifestyle (regular 
exercise, healthy 
weight, no smoking, 
dietary counseling)
Treatment goals are 
based on overall risk 
of heart disease (eg, 
>10% chance of 
coronary heart 
disease in 10 years). 
Overall risk 
assessment will 
include the 
following risk 
factors: age, sex, 
diabetes, clinical 
atherosclerotic 
disease, 
hypertension, family 
history, low HDL 
(<40 mg/dL or 1.0 
mmol/L), and 
smoking.
Non-pharmacologic interventions: 
CHILD-1diet, activity education, 
and weight management
If LDL goals not achieved after 6 
months on non-pharmacologic 
intervention, consider statin 
therapy if age >10 years to achieve 
tier I treatment goals for LDL
Lifestyle modifications and 
lipid lowering therapies to 
achieve risk-adapted target 
for LDL is primary goal
The decision to initiate 
lipid lowering therapy 
should include assessment 
of overall risk of heart 
disease. (http://
cvdrisk.nhlbi.nih.gov)
If TG>500 mg/dL (5.65 
mmol/L), initiate fibrate or 
nicotinic acid
Blood pressure control For BP >120/80 mm 
Hg: Initiate or 
maintain lifestyle 
modifications
For BP >140/90 mm 
Hg (or >130/80 mm 
Hg for individuals 
with chronic kidney 
disease or diabetes): 
As tolerated, add BP 
medication as needed 
to achieve goal BP
Non-pharmacologic 
treatments may also 
be tried for mild 
hypertension and 
include moderate 
dietary sodium 
restriction, weight 
reduction in the 
obese, avoidance of 
excess alcohol 
intake, and regular 
aerobic exercise.
Treatment is 
indicated for 
readings >140/90 in 
adults on two 
separate visits at 
least 1 week apart, 
unless hypertension 
is mild or can be 
attributed to a 
temporary condition 
or medication (eg, 
cyclosporine).
Non-pharmacologic interventions: 
CHILD-1 diet, activity education, 
and weight management
Up-front initiation of anti-HTN 
therapy for Stage II HTN; 
initiation of anti-HTN therapy for 
Stage I HTN if no response to 6 
months of non-pharmacologic 
intervention
Non-pharmacologic 
treatments may also be 
tried for mild hypertension 
and include moderate 
dietary sodium restriction, 
weight reduction in the 
obese, avoidance of excess 
alcohol intake, and regular 
aerobic exercise.
Treatment is indicated for 
readings >140/90 in adults 
on two separate visits at 
least 1 week apart, unless 
hypertension is mild or can 
be attributed to a temporary 
condition or medication 
(eg, cyclosporine).
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General adult 
population
(Grundy. 
Circulation. 2005)
Adult long-term 
HCT survivors
(Majhail. BBMT. 
2012)
General pediatric population
(http://www.nhlbi.nih.gov)
Our recommendations
(CIBMTR/EBMT MetS 
collaboration)
Glycemic control For IFG, encourage 
weight reduction and 
increased physical 
activity.
For type 2 DM, 
lifestyle therapy, and 
pharmacotherapy, if 
necessary, should be 
used to achieve near-
normal HbA1C 
(<7%).
Recommend 
education and 
counseling on 
“heart” healthy 
lifestyle (regular 
exercise, healthy 
weight, no smoking, 
dietary counseling)
Non-pharmacologic interventions: 
CHILD-1 diet, activity education, 
and weight management
Consultation with an 
endocrinologist as needed to 
maintain optimal plasma glucose 
and HbA1c for age.
For IFG, encourage weight 
reduction and increased 
physical activity.
For type 2 DM, lifestyle 
therapy, and 
pharmacotherapy, if 
necessary, should be used 
to achieve near-normal 
HbA1C (<7%).
*NCI/NHLBI Pediatric BMT Consortium publication (Pulsipher. BBMT. 2012) does not provide preventive practice recommendations
Abbreviations: BP, blood pressure; CIBMTR, Center for International Blood and Marrow Transplant Research; CHILD-1, Cardiovascular Health 
Integrated Lifestyle Diet; DM, diabetes mellitus; EBMT, European Group for Blood and Marrow Transplantation; HbA1C, hemoglobin A1C; HCT, 
hematopoietic cell transplantation; HDL, high-density lipoprotein cholesterol; HTN, hypertension; IFG, impaired fasting glucose; LDL, low-
density lipoprotein; TG, triglycerides
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Table 4
CIBMTR/EBMT screening guidelines and preventive practice recommendations for 
metabolic syndrome and cardiovascular risk factors for adult and pediatric patients 
amongst the general population and HCT survivors
Screening guidelines Preventive practice
Weight, Height, BMI Weight, height, and BMI assessment at every clinic visit 
(at least yearly)
Waist circumference measurement yearly
Consider DXA to assess sarcopenia
Provide advice regarding intensive, multicomponent 
behavioral interventions focused on achieving and 
maintaining healthy weight by reducing caloric intake 
and increasing physical activity
Dyslipidemia For all allo-HCT recipientes, initial lipid profile 3 months 
after HCT.
For high-risk patients with ongoing risk factors (including 
those on sirolimus, calcineurin inhibitors, corticosteroids), 
repeat evaluation every 3-6 months.
For standard-risk patients, lipid profile assessment every 5 
years in males aged ≥35 years and females aged ≥45 years. 
The interval for screening should be shorter for people 
who have lipid levels close to those warranting therapy.
Lifestyle modifications and lipid lowering therapies to 
achieve relative reductions in LDL is the primary goal
In adults, the decision to initiate lipid lowering therapy 
should include assessment of overall risk of heart 
disease (http://cvdrisk.nhlbi.nih.gov).
If TG>500 mg/dL (5.65 mmol/L), initiate fibrate or 
nicotinic acid
Blood Pressure Blood pressure assessment at every clinic visit (at least 
yearly)
Non-pharmacologic treatments may also be tried for 
mild hypertension and include moderate dietary sodium 
restriction, weight reduction in the obese, avoidance of 
excess alcohol intake, and regular aerobic exercise.
Treatment is indicated for readings >140/90 in adults on 
two separate visits at least 1 week apart, unless 
hypertension is mild or can be attributed to a temporary 
condition or medication (eg, cyclosporine).
Hyperglycemia For high-risk patients with ongoing risk factors (including 
those on systemic corticosteroids), screen for abnormal 
blood glucose (HbA1C or fasting plasma glucose) 3 
months after HCT with repeat evaluation every 3-6 
months.
For standard-risk adult patients, screening for abnormal 
blood glucose every 3 years in adults aged ≥45 years or in 
those with sustained higher blood pressure (>135/80 mm 
Hg)
For standard-risk pediatric patients, fasting glucose at least 
every 5 years; if abnormal, screen annually
For IFG, encourage weight reduction and increased 
physical activity.
For type 2 DM, lifestyle therapy, and pharmacotherapy, 
if necessary, should be used to achieve near-normal 
HbA1C (<7%).
Abbreviations: BMI, body mass index; CIBMTR, Center for International Blood and Marrow Transplant Research; DM, diabetes mellitus; DXA, 
dual X-ray absorptiometry; EBMT, European Group for Blood and Marrow Transplantation; HbA1C, hemoglobin A1C; HCT, hematopoietic cell 
transplantation; IFG, impaired fasting glucose; LDL, low-density lipoprotein; TG, triglycerides
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Table 5
Risk factors to consider when screening for components of metabolic syndrome in 
transplant recipients
• Personal history
• Family history
• Type of transplant (allogeneic or autologous)
• TBI as part of pre-transplant conditioning
• Development of acute or chronic GVHD
• Ongoing therapy with corticosteroids
• Ongoing therapy with calciunerin inhibitors
• Ongoing therapy with sirolimus
• Presence of additional metabolic syndrome components
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